📣 VC round data is live. Check it out!
- Public Comps
- Veradigm
Veradigm Valuation Multiples
Discover Veradigm's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Guiyang Longmaster, GPI Group, Heren Health, Claritev and more.
Veradigm Overview
About Veradigm
Veradigm Inc is a healthcare technology company that drives value through its various combinations of platforms, data, expertise, connectivity, and scale. The company delivers a combination of point-of-care clinical and financial solutions. The Veradigm Network features a dynamic community of solutions and partners providing insights, technology, and data-driven solutions for the healthcare provider, payer, and Life Science markets.
Founded
2000
HQ

Employees
2.6K
Website
Sectors
Financials (LTM)
EV
$279M
Valuation Multiples
Start free trialVeradigm Financials
Veradigm reported last 12-month revenue of $586M and EBITDA of $82M.
In the same LTM period, Veradigm generated $323M in gross profit, $82M in EBITDA, and $32M in net income.
Revenue (LTM)
Veradigm P&L
In the most recent fiscal year, Veradigm reported revenue of - and net income of -.
Financial data powered by Morningstar, Inc.
Veradigm Stock Performance
Veradigm has current market cap of $506M, and enterprise value of $279M.
Market Cap Evolution
Veradigm's stock price is $4.65.
Veradigm share price decreased by 1.1% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $279M | $506M | 0.0% | - | 0.0% | -1.1% | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVeradigm Valuation Multiples
Veradigm trades at 0.5x EV/Revenue multiple, and 3.4x EV/EBITDA.
EV / Revenue (LTM)
Veradigm Financial Valuation Multiples
As of June 3, 2026, Veradigm has market cap of $506M and EV of $279M.
Veradigm has a P/E ratio of 15.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Veradigm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Veradigm Margins & Growth Rates
Veradigm Margins
Veradigm Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Veradigm Operational KPIs
Veradigm's Rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Veradigm's Rule of X is 15% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Veradigm Competitors
Veradigm competitors include Guiyang Longmaster, GPI Group, Heren Health, Claritev, Weave Communications, Artrya, Evolent Health, Goodwill E-Health Info, Medley Inc. and Shang Gong Group.
Most Veradigm public comparables operate across Healthcare Software, EHR & Practice Management, Health Data & Analytics, B2B SaaS, Vertical SaaS and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 10.8x | - | 85.6x | - | |||
| 1.4x | 1.3x | 6.7x | 6.4x | |||
| 6.5x | - | 34.9x | - | |||
| 5.4x | 5.3x | 8.6x | 8.6x | |||
| 1.9x | 1.8x | 58.8x | 39.0x | |||
| 24054.7x | 164.7x | (50.1x) | (34.8x) | |||
| 0.7x | 0.6x | 8.5x | 9.2x | |||
| 7.8x | 7.2x | (13.6x) | (20.0x) | |||
This data is available for Pro users. Sign up to see all Veradigm competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Veradigm
Veradigm has acquired 10 companies to date.
Last acquisition by Veradigm was on February 27th 2024. Veradigm acquired ScienceIO for $140M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Veradigm
| Description | ScienceIO is a Massachusetts-based biomedical AI firm founded in 2019. It processes unstructured medical text to extract entities, clinical variables, and codes, enabling queries across electronic health records for drug discovery and research. | Koha Health is a Merrimack-headquartered healthcare provider founded in 1984 offering orthopedic practices, physical therapy, and musculoskeletal diagnostics. The center delivers comprehensive services including sports medicine and rehabilitation for patients in New Hampshire. | ZappRx is a Boston-based digital health company that streamlines specialty drug management through a secure online platform. It connects patients, physicians, and pharmacists to accelerate treatment access and medication delivery. The system handles prior authorizations, benefits verification, and prescription fulfillment for therapies in oncology, rare diseases, and other complex areas. | HealthGrid Corp supplies mobile patient engagement solutions integrated into provider workflows, boosting satisfaction for independent practices, hospitals, and health systems amid value-based care shifts and low portal adoption rates. | |
| HQ Country | |||||
| HQ City | Boston, MA | - | Boston, MA | Orlando, FL | |
| Deal Date | 27 Feb 2024 | 2 Jan 2024 | 13 Jun 2019 | 3 May 2018 | |
| Valuation | $140M | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Veradigm acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Veradigm
Veradigm has invested in 3 companies to date.
Latest investment by Veradigm was on October 2nd 2023. Veradigm invested in Holmusk in their $30M Strategic investment round (EV/Revenue multiple available to Pro users).
Latest Investments by Veradigm
| Description | Holmusk is a New York City-headquartered platform aggregating real-world evidence from behavioral health electronic health records for chronic disease management. The Holmusk Insights engine processes de-identified data from over 7 million patient lives across 200 providers in the US and UK. It supports pharmaceutical firms like Janssen in drug commercialization and clinicians at facilities like NYU Langone with treatment decision tools. Founded in 2015, Holmusk partners with payers including Aetna to advance evidence-based care in mental health. | Holmusk is a New York City-headquartered platform aggregating real-world evidence from behavioral health electronic health records for chronic disease management. The Holmusk Insights engine processes de-identified data from over 7 million patient lives across 200 providers in the US and UK. It supports pharmaceutical firms like Janssen in drug commercialization and clinicians at facilities like NYU Langone with treatment decision tools. Founded in 2015, Holmusk partners with payers including Aetna to advance evidence-based care in mental health. | Hospital IQ is a predictive analytics platform optimizing hospital operations through operations research. It partners with institutions like Brigham and Women’s Hospital to enhance capacity planning, scheduling, staffing, utilization, and throughput across single sites or networks. Automated tools deliver reporting, modeling, and forecasts for data-driven decisions in patient flow and resource allocation. | NantHealth is a Culver City, California-headquartered precision medicine company that delivers genomic sequencing and molecular diagnostics through its Navify platform for oncology and rare diseases. The firm integrates multi-omic data to guide personalized treatment decisions in partnerships with hospitals across the United States. |
| HQ Country | ||||
| HQ City | Singapore | Singapore | Boston, MA | Los Angeles, CA |
| Deal Date | 2 Oct 2023 | 9 Jan 2023 | 28 Jun 2021 | 26 Jun 2015 |
| Round | Strategic investment | Series B | Series C | Undisclosed stage |
| Raised | $30M | $45M | $25M | $200M |
| Investors | Veradigm | Health Catalyst Capital; Heritas Capital; Northwell Ventures; Novartis; Veradigm | Baxter Ventures; Health Velocity Capital; Longworth Venture Partners; Pierpoint Capital; Veradigm | Veradigm |
| Valuation | undisclosed | undisclosed | undisclosed | $2B |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Veradigm investments and their VC round multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Veradigm
| When was Veradigm founded? | Veradigm was founded in 2000. |
| Where is Veradigm headquartered? | Veradigm is headquartered in United States. |
| How many employees does Veradigm have? | As of today, Veradigm has over 2K employees. |
| Is Veradigm publicly listed? | Yes, Veradigm is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Veradigm? | Veradigm trades under MDRX ticker. |
| When did Veradigm go public? | Veradigm went public in 1999. |
| Who are competitors of Veradigm? | Veradigm main competitors include Guiyang Longmaster, GPI Group, Heren Health, Claritev, Weave Communications, Artrya, Evolent Health, Goodwill E-Health Info, Medley Inc., Shang Gong Group. |
| What is the current market cap of Veradigm? | Veradigm's current market cap is $506M. |
| What is the current revenue of Veradigm? | Veradigm's last 12 months revenue is $586M. |
| What is the current revenue growth of Veradigm? | Veradigm revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Veradigm? | Current revenue multiple of Veradigm is 0.5x. |
| What is the current EBITDA of Veradigm? | Veradigm's last 12 months EBITDA is $82M. |
| What is Veradigm's EBITDA margin? | Veradigm's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Veradigm? | Current EBITDA multiple of Veradigm is 3.4x. |
| What is the current FCF of Veradigm? | Veradigm's last 12 months FCF is ($32M). |
| What is Veradigm's FCF margin? | Veradigm's last 12 months FCF margin is (5%). |
| What is the current EV/FCF multiple of Veradigm? | Current FCF multiple of Veradigm is (8.8x). |
| How many companies Veradigm has acquired to date? | As of June 2026, Veradigm has acquired 10 companies. |
| What was the largest acquisition by Veradigm? | $185M acquisition of McKesson (enterprise information solutions unit) on 3rd August 2017 was the largest M&A Veradigm has done to date. |
| What companies Veradigm acquired? | Veradigm acquired McKesson (enterprise information solutions unit), ScienceIO, Practice Fusion, Oasis Medical Solutions, Core Medical Solutions, CarePort Health, Netsmart Technologies, Koha Health, ZappRx, and HealthGrid Corp.. |
| In how many companies Veradigm has invested to date? | As of June 2026, Veradigm has invested in 3 companies. |
| What was the last Veradigm investment? | On 2nd October 2023 Veradigm invested in Holmusk, participating in a $30M Strategic investment round. |
| In what companies Veradigm invested in? | Veradigm invested in NantHealth, Holmusk, and Hospital IQ. |
See public comps similar to Veradigm
Lists including Veradigm
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

